Streetbeat News

Stock Prices

AVDE

AVSD

UBS

UBS Group AG has placed a $2 billion Credit Suisse real estate fund into liquidation due to significant value decline and high redemptions. UBS reported strong Q2 FY24 sales and EPS, beating consensus estimates. UBS shares are down 2.33% premarket.

Portfolio Pulse from Lekha Gupta

August 15, 2024 | 1:00 pm

WELL

Analysts have provided mixed ratings for Welltower (NYSE:WELL) over the past three months, with a recent increase in average price targets. The company's financial performance has been strong, with notable revenue growth, net margin, and efficient debt management.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

GILD

Over the past three months, 8 analysts have shared their insights on Gilead Sciences (NASDAQ:GILD), with opinions ranging from bullish to bearish. The average 12-month price target has increased to $77.25 from $74.86. Key analysts have adjusted their ratings and price targets, reflecting their responses to recent developments. Gilead Sciences shows strong financial metrics, including a net margin of 23.21% and a return on equity of 9.01%.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

GLBE

Over the past three months, 12 analysts have shared their evaluations of Global E Online (NASDAQ:GLBE), with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $44.42, slightly up from the previous $44.09. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a generally positive outlook for the company.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

RSKD

Analysts have provided mixed ratings for Riskified (NYSE:RSKD) over the past three months, with a recent average 12-month price target of $6.25, reflecting a 4.17% increase from the previous target. Key analysts from Piper Sandler, Goldman Sachs, UBS, and Barclays have adjusted their ratings and price targets, indicating varied expectations for the company's future performance.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

OMGA

Over the past three months, four analysts have evaluated Omega Therapeutics (NASDAQ:OMGA), with ratings ranging from bullish to bearish. The average 12-month price target is $10.5, with a high of $12.00 and a low of $6.00. Recent ratings include 'Buy' and 'Outperform' from HC Wainwright & Co., Wedbush, and Raymond James, while Chardan Capital lowered its target from $7.00 to $6.00. Omega Therapeutics has shown significant revenue growth but faces challenges with high debt levels and low ROE.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

GOEV

Canoo shares are trading higher following Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:59 pm

FFNTF

4Front Ventures Corp. (OTCQX: FFNTF) reported a 31% YoY decrease in Q2 revenue to $18.7 million. Despite this, the company reduced its net loss to $4.87 million from $11.46 million last year. The Illinois facility saw a slight revenue drop but a 10% increase in wholesale revenue. Massachusetts showed a positive trend with a 31% growth in wholesale revenue. The company is expanding its Matteson, Illinois facility and introduced a new vape product. Shares closed 4.03% higher at $0.062.

Portfolio Pulse from Nina Zdinjak

August 15, 2024 | 12:55 pm

QNTM

Trading halt status was updated at 8:55:00 AM ET, indicating a resumption of quotations. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:55 pm

GRAB

Grab Holdings Limited (NASDAQ:GRAB) reported Q2 2024 revenue growth of 17% year-on-year to $664 million, missing the analyst consensus estimate of $669.25 million. EPS of $(0.01) was in line with expectations. Despite growth in various segments, the average spend per user decreased by 6% year-on-year. The stock price dropped by 8.31% premarket following the results.

Portfolio Pulse from Anusuya Lahiri

August 15, 2024 | 12:55 pm